Atezolizumab Plus Bevacizumab Improves Overall Survival in Unresectable HCC Compared with Sorafenib

Atezolizumab combined with bevacizumab improves overall and progression-free survival outcomes compared with sorafenib in patients with unresectable hepatocellular carcinoma, according to an article in New England Journal of Medicine.

The randomized phase 3 IMbrave150 study found that overall survival at 12 months in patients treated with the combination therapy was 67.2% compared with 54.6% in patients treated with sorafenib. Patients treated with atezolizumab–bevacizumab had a median progression-free survival of 6.8 months compared with 4.3 month in those treated with sorafenib.

Read the full article here.

–Kelsey Moroz

Reference

Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020; 382:1894-1905. DOI: 10.1056/NEJMoa1915745